Risk Register:	Corporate Risk Register
Date updated:	January 2019 for ARC & Board (Q3 2018/19)

HRA Risk Reference	Directorate Risk Reference	Risk Category	Date Raised	Risk Description	Timing	Inherent Likelihood Score	Inherent Impact Score	Inherent Risk Score	Risk Owner	Controls and Mitigations	Implementation date	Action Owner	Residual Likelihood Score	Residual Impact Score	Residual Risk score	Trend	Target Residual Risk Score	Assurance group / source	Contingency	Date risk last reviewed
HRA288	PPA013	Policy	04.02.2015	**Risk:** Unknowns around scope around Social Care and uncertainty of funding to deliver mean we may not be fulfilling our statutory responsbilities **Cause:** Despite the HRA listening exercises there remains significant unknowns about the volume of social care research and mixed views on how the HRA should implement its role for adult social care **Effect:** HRA may be seen to have failed to embrace the broader remit, equally in bringing in to remit beyond the current Social Care REC there are risks associated with a significant programme of change	Imminent	5	4	20	JT	**RM1** - Clear messaging to set out the current objectives and focus of HRA Approval on NHS. **RM2 -** Maintaining Social Care REC within the overall Research Ethics Service and ensuring social studies reviewed by this REC. **RM3** - Updating website to make it social care friendly	Ongoing	AH	4	3	12	⇆	10	Board and LT		01/01/2019
HRA608	App155	Approval - Prjoects	08/02/2018	**Risk:** delay in research starting at participating NHS organisation **Cause:** sites refusing to receive local information packs because they are not ready to start and perceive a negative impact on the metrics they are required to report **Effect:** researchers not seeing the benefits of HRA Approval in terms of improving study set up times and also seeing different processes emerging when working with NHS organisations	Imminent	4	4	16	JMe	**RM1:** Local information packs incorporated into IRAS, ensuring phrasing for rejection states "we do not wish to participate" rather than provide means to reject/delay involvement because site not ready (end of Sept 2018) **RM2:** JH to continue working with NHS organisations and also raise with R&D Champions Group - COMP (JH has raised with R&D Champions Group) **RM3:** Further development of UK-wide metrics to address behaviour **RM4:** communications and work with CRN on reporting of high level objectives to make sure don't drive people to rejects packs	16/01/2019	JH	3	4	**12**	⇊	4	HRA Approval Projects Group		18/10/2018
HRA673	PPA016	Policy	21/01/2019	**Risk:** That we fail to address recommendations from the HoC Science & Technology Committee around clinical trials transparency **Cause:** Lack of resources, legal powers and stakeholder buy-in **Effect:** That external audiences lose faith in HRA's ability to improve research transparency, research waste remains and patients enrolled in unnecessary studies	Medium	4	4	16	JT	**RM1** - Positive response to committee, in comms and face-to-face meeting, to convey that we're taking this seriously **RM2** - Legal advice on powers commissioned and compliance options explored **RM3** - Discussion with DHSC on cost of monitoring function commenced **RM4** - Strategy development, with careful engagement, planned for 2019 **RM5** - Using opportunity of IRAS redevelopment to build in functionaltiy to prompt action and automate publication of performance of individual studies	End 2019	JT	3	4	12	NEW	6	LT		21/01/2019